Resverlogix Corp.

Resverlogix Corp.

Resverlogix Corp.

RVX-208 is a first-in-class, selective BET bromodomain inhibitor treating patients with cardiovascular disease, diabetes mellitus, and other serious diseases.
Founded
2001
Raised
$67.3M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$10,000,000
Post-IPO equity - 2017
Eastern Capital Shenzhen Hepalink Pharmaceutical Co Ltd
$30,000,000
Post-IPO debt - 2014
Team Size
10+
Employees
Location
Headquarters
$10,000,000 Post-IPO equity
PE HUB

Eastern, Hepalink invest in Resverlogix's $10 mln offering

Stock markets Privacy Health